Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Receivables (2020 - 2024)

Barinthus Biotherapeutics' Receivables history spans 5 years, with the latest figure at $7.1 million for Q4 2024.

  • For Q4 2024, Receivables rose 45.46% year-over-year to $7.1 million; the TTM value through Dec 2024 reached $7.1 million, up 45.46%, while the annual FY2024 figure was $7.1 million, 45.46% up from the prior year.
  • Receivables reached $7.1 million in Q4 2024 per BRNS's latest filing, up from $5.2 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $22.8 million in Q1 2022 to a low of $2.7 million in Q1 2023.
  • Average Receivables over 5 years is $6.7 million, with a median of $5.1 million recorded in 2023.
  • Peak YoY movement for Receivables: surged 469.3% in 2022, then tumbled 88.27% in 2023.
  • A 5-year view of Receivables shows it stood at $3.2 million in 2020, then soared by 93.71% to $6.2 million in 2021, then soared by 60.68% to $10.0 million in 2022, then tumbled by 51.12% to $4.9 million in 2023, then soared by 45.46% to $7.1 million in 2024.
  • Per Business Quant, the three most recent readings for BRNS's Receivables are $7.1 million (Q4 2024), $5.2 million (Q1 2024), and $4.9 million (Q4 2023).